For the first time, a complete pathway from early detection to treatment exists for Alzheimer's disease — and primary care sits at the front of it. Three major developments in early 2026 are reshaping how clinicians identify and act on cognitive decline. In this session, Dr. Stephen Bekanich, Chief Medical Officer at BrainCheck, breaks down what's changed, what's ready for practice now, and how to connect all three pieces in a real PCP workflow — with Phyllis Ferrell, Advisor at PBFerrell LLC, moderating the conversation. You'll walk away understanding:
- Why 95% of PCPs want digital cognitive assessments but most still aren't using them, and what changes that
- What the Alzheimer's Association and CEOi blood-based biomarker guideline means — and what it doesn't yet cover for primary care
- The state of anti-amyloid therapy in 2026, including real-world persistence data and the expanding treatment landscape
- How the MCI window defines your opportunity — and why timing in the detection sequence is everything
The treatment window is narrow. The tools to catch patients in it are here.
Download Slides